Generate Biomedicines pushes machine learning to create new protein drugs
Generate Biomedicines is using machine learning in the U.S. to design new protein drugs. Its pipeline includes candidates for severe asthma and CAR-T cell therapy.
United States Biotech 3 articles
United States Biotech covers the American biotechnology ecosystem from research commercialization and company formation to public markets, clinical development, manufacturing and FDA-centered regulation. The section is geographic rather than thematic, so stories qualify when the United States is the dominant institutional or business context. Cross-border comparisons move to Global Biotech, while non-US regional developments remain in their dedicated sections unless they materially reshape the American biotech landscape.
DARPA puts AI at the core of its biotech program management
DARPA has handed Systems Planning and Analysis a $10.9 million contract to run its biotechnology projects with AI support through 2031. This marks a sharp turn toward AI-driven oversight in U.S. defense biotech.
Rheumatologist trust in CAR T therapies drops after safety scares, but autologous approach still leads
Recent deaths and severe side effects in CAR T trials have rattled rheumatologists. Despite the drop in confidence, autologous CAR T remains the top pick, even as new hurdles emerge.